Title

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.

Authors

Nathan H Fowler
Loretta Nastoupil
Sven De Vos
Mark Knapp
Ian W Flinn
Robert Chen
Ranjana H Advani
Sumeet Bhatia
Peter Martin
Raul Mena, Providence St. Joseph Medical Center, Burbank, CA, USAFollow
Richard Eric Davis
Sattva S Neelapu
Karl Eckert
Jerry Ping
Melannie Co
Darrin M Beaupre
Jutta K Neuenburg
M Lia Palomba

Document Type

Article

Publication Date

3-16-2020

Publication Title

British journal of haematology

Keywords

follicular lymphoma; ibrutinib; rituximab

Abstract

This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton's tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once-daily ibrutinib 560 mg continuously plus once-weekly rituximab 375 mg/m

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Recommended Citation

Fowler, Nathan H; Nastoupil, Loretta; De Vos, Sven; Knapp, Mark; Flinn, Ian W; Chen, Robert; Advani, Ranjana H; Bhatia, Sumeet; Martin, Peter; Mena, Raul; Davis, Richard Eric; Neelapu, Sattva S; Eckert, Karl; Ping, Jerry; Co, Melannie; Beaupre, Darrin M; Neuenburg, Jutta K; and Palomba, M Lia, "The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma." (2020). Articles, Abstracts, and Reports. 2952.
https://digitalcommons.providence.org/publications/2952